Selected passages from the FDA letter
Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.
Passage 1You failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].
Citations in the original letter
As cited in this historical letter, not a statement of current regulatory requirements.
- 21 CFR 312.2(a)
- 21 CFR 312.2
- 21 CFR 312
- 21 CFR 312.20(a)
- 21 CFR 312.20
- 21 CFR 312.21
- 21 CFR 312.40